EP Patent

EP2191833A1 — Transdermally absorbable preparation

Assigned to Shiseido Co Ltd · Expires 2010-06-02 · 16y expired

What this patent protects

[PROBLEMS] To improve the stability of a natural type sex hormone and the permeation in a transdermally absorbable preparation containing the natural type sex hormone to thereby increase the systemic effect and the long-acting property of the preparation. [MEANS FOR SOLVING…

USPTO Abstract

[PROBLEMS] To improve the stability of a natural type sex hormone and the permeation in a transdermally absorbable preparation containing the natural type sex hormone to thereby increase the systemic effect and the long-acting property of the preparation. [MEANS FOR SOLVING PROBLEMS] The preparation comprises a natural type sex hormone, a polyoxyethylene oleyl ether having a molar number of ethylene oxide units added of 20, at least two kinds of oily ingredients selected from the group consisting of diisopropyl adipate, cetyl alcohol, benzyl alcohol, and propylene glycol dicaprate, a polyhydric alcohol, and ethanol.

Drugs covered by this patent

Patent Metadata

Patent number
EP2191833A1
Jurisdiction
EP
Classification
—
Expires
2010-06-02
Drug substance claim
No
Drug product claim
No
Assignee
Shiseido Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.